The molecule is in the address and nowhere else
We extracted both product pages and searched them. Across seven thousand and ninety-five characters on one and seven thousand one hundred and eighty-five on the other, the word semaglutide appears zero times and the word tirzepatide appears zero times. What appears instead is GLP-1, seven times on one page and four on the other, and GIP twice on the second.
So the only place either drug is named is the address bar. A reader who arrives from a search for semaglutide will find a page that never confirms it is selling semaglutide.
Twenty of the one hundred and fifty-eight sellers here put a price beside a product they will only call a GLP-1. It is the single most consequential omission a seller can make, because the two molecules are not interchangeable, are not equivalently dosed, and do not cost the same anywhere else on this roster.
Two discounts, one anchor, one page
On each product page, an upper block prints a struck-through monthly figure and a discounted one. A second block lower down prints the same struck-through figure and a different, higher discounted one. Both blocks describe what reads as the same product.
The page does not say whether the second is a different dose, a different term, or a different plan. We have recorded both, on both pages, with the anchor named in each qualifier, because recording one would be choosing a side of a conflict the seller has not resolved.
The anchor itself is worth crediting. A struck-through price is a claim about what the thing costs without the discount, and printing it is more informative than a bare as-low-as figure. It also means the discount has a stated size, which is unusual here.
What else is on the page
The seller states that there are no hidden fees and that pricing is consistent at all dosages. Neither sentence answers whether a membership applies, so we have recorded that as unstated; sixty-four of the one hundred and fifty-eight sellers here leave it unstated.
The operating company is self-identified in the opening sentence of the privacy policy, which also names a clinical practice and, in the Terms, a platform vendor. Those two vendor names recur across a dozen apparently unrelated GLP-1 brands, which is worth knowing when a reader treats brand independence as a signal.
No compounding pharmacy is named and no individual clinician is named. No service area is published.
Ark Health's published pricing
| Medication | Price | Verified |
|---|---|---|
| Glp-1 (compounded) | $169/moper month, discounted from a struck-through $399/mo on the same card; the seller names no molecule beside either figure | September 2026source |
| Glp-1 (compounded) | $299/moper month, discounted from the same struck-through $399/mo, in a second block lower on the same page; the page does not say what distinguishes the two | September 2026source |
| Glp-1 (compounded) | $249/moper month on the dual GLP-1 and GIP page, discounted from a struck-through $499/mo; the seller names no molecule beside either figure | September 2026source |
| Glp-1 (compounded) | $399/moper month, discounted from the same struck-through $499/mo, in a second block lower on the same page; the page does not say what distinguishes the two | September 2026source |
compareglp may earn a commission when a reader signs up with a provider through a link on this site. 4 of the 158 providers reviewed here are paid partners today; the other 154 are not. See how this works.
See Ark Health's current price →Good fit if
- Readers who want to see the undiscounted anchor a promotional price is measured against.
- Buyers who want a written statement that the price holds as the dose rises.
Look elsewhere if
- Anyone who needs to know which drug they are buying. Neither product page names a molecule in its visible text.
- Readers who need one price per product. Each page carries two discounted figures against one anchor.
- Buyers who want the compounding pharmacy or a prescribing clinician named, or a service-area list.
- People who want the membership question answered.
How this review was verified
- Re-read both product pages and the privacy policy on 6 September 2026, comparing the requested path to the effective path and running a nonsense path against the host in the same run.
- Ran a word census over the extracted text of both product pages for semaglutide, tirzepatide, GLP-1 and GIP, and recorded the counts rather than inferring the molecule from the page address.
- Recorded all four published figures, two per page, rather than choosing the lower or the more prominent of each pair.
- Read the operating entity off the opening sentence of the privacy policy, and the clinical and platform vendors off the Terms.
- Screened the operating entity and the brand name against FDA's live warning-letter record with a known letter as a positive control and a nonsense string as a negative control in the same pass. Neither returned a letter. Untitled letters are published separately and were not searched.